Age: Addressing a Blind Spot in Cancer Care

Our Purpose
Health Equity Article_790x500.png
Health Equity Article_1000x450.jpg

Age: Addressing a Blind Spot in Cancer Care

at pfizer, we’re focused on removing barriers for all people living with cancer – including those over the age of 65 – to address disparities in cancer care and improve health equity.

GET TO KNOW DR. ANNALIESA ANDERSON, HEAD OF BACTERIAL VACCINES

Our People
Get to know DR. Annaliesa Anderson
Get to know DR. Annaliesa Anderson

GET TO KNOW DR. ANNALIESA ANDERSON, HEAD OF BACTERIAL VACCINES

find out what life is like for her, and our other scientists, in the time of coronavirus.

PROFESSOR JOE SCHMITT TALKS TICK-BOURNE ENCEPHALITIS

Health
TBE_Image_380x500.jpg
TBE_Image_1000x450.jpg

PROFESSOR JOE SCHMITT TALKS TICK-BOURNE ENCEPHALITIS

捕鱼棋牌网站ticks may be tiny, but the diseases they carry can have a big impact.

HOW ARE VACCINES DEVELOPED?

Our Science
How are vaccines Developed?
How are vaccines Developed?

HOW ARE VACCINES DEVELOPED?

捕鱼棋牌网站explore what it takes to develop a novel vaccine.

Find a Trial

捕鱼棋牌网站search for clinical trials by condition, keyword or trial number. share your location or enter your city or zip code to find studies near you.

COVID-19 AND CANCER

Your Health
COVID-19 and Cancer
COVID-19 and Cancer

COVID-19 AND CANCER

捕鱼棋牌网站we answer questions about the impact of coronavirus on people with cancer, safeguards they can take to stay healthy & more.

WHAT YOU NEED TO KNOW ABOUT COVID-19

Your Health
What you need to know about COVID-19
What you need to know about COVID-19

WHAT YOU NEED TO KNOW ABOUT COVID-19

practical advice to protect you and your family from coronavirus.

Latest News

Darmstadt, Germany, and New York, US, June 22, 2020 – Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency (EMA) has validated for review the Type II variation application for BAVENCIO® (avelumab) for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC). With this validation, the application is…